title: Short-term safety assessment in the use of intravenous zoledronic acid in children.
abstract: The clinical side effects of the potent new bisphosphonate zoledronic acid in children are unknown. In this study of 34 children with various bone disorders, the frequency of postinfusion flu-like illness, hypocalcemia, and hypophosphatemia was 85%, 74%, and 82%, respectively. No renal side effects were detected after up to 3 consecutive infusions.
authors.affiliation: Institute of Endocrinology and Diabetes, Department of Orthopedics, The Children's Hospital of Westmead, Sydney, Australia.
authors.forename: Wolfgang
authors.initials: W
authors.lastname: Högler
authors.forename: Fabian
authors.initials: F
authors.lastname: Yap
authors.forename: David
authors.initials: D
authors.lastname: Little
authors.forename: Geoffrey
authors.initials: G
authors.lastname: Ambler
authors.forename: Mary
authors.initials: M
authors.lastname: McQuade
authors.forename: Christopher T
authors.initials: CT
authors.lastname: Cowell
mesh_terms: D000293:Adolescent; D001862:Bone Resorption / Q000378:metabolism* / Q000517:prevention & control; D002118:Calcium / Q000097:blood; D002648:Child; D002675:Child, Preschool; D003404:Creatinine / Q000097:blood; D004164:Diphosphonates / Q000008:administration & dosage / Q000009:adverse effects*; D005260:Female; D005334:Fever / Q000139:chemically induced; D005500:Follow-Up Studies; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage / Q000009:adverse effects*; D007262:Infusions, Intravenous; D008297:Male; D009325:Nausea / Q000139:chemically induced; D010146:Pain / Q000139:chemically induced; D010758:Phosphorus / Q000097:blood; D012189:Retrospective Studies; D013997:Time Factors; D014508:Urea / Q000097:blood; D014839:Vomiting / Q000139:chemically induced; D000077211:Zoledronic Acid
chemical_list: D004164:Diphosphonates; D007093:Imidazoles; D010758:Phosphorus; D000077211:Zoledronic Acid; D014508:Urea; D003404:Creatinine; D002118:Calcium